Review Article
Gallbladder Cancer in the 21st Century
Table 7
Targeted therapy alone or in combination with chemotherapy in gallbladder and biliary tract cancer.
| Targeted agent | Disease site | Number GBC/total | Line of therapy | Response rate | Comments |
| Single agent targeting VGF | | | | | | Sorafenib [145] | BTC | 12/31 | First | 6% | | Sunitinib [146] | BTC | NA/56 | Second | 9% | | Single agent targeting HER2 | | | | | | Lapatinib [147] | HCC or BTC | 17 BTC/57 | First & second | 0% in BTC | | Lapatinib [148] | HCC or BTC | NA/9 | Any | 0% | Trial was stopped early due to futility | Other single agents | | | | | | Bortezomib [149] | BTC | 6/20 | First, second, third | 5% | Trial was stopped early due to futility | Selumetinib [150] | BTC | 7/28 | Second | 10% | | Doublet of targeted agents | | | | | | Bevacizumab + erlotinib [151] | BTC | 10/53 | First | 17% | | Bevacizumab + erlotinib [152] | Upper GI cancer | 16 BTC/102 | Second or later | 6% | | Targeted agents with chemotherapy | | | | | | GEMOX ± cetuximab [153] | BTC | NA/50 | First | 23% | Response rate in control group: 29% | GEMOX + cetuximab [154] | BTC | NA/30 | First | 63% | 9 patients underwent resection after response | GEMOX ± cetuximab [155] | BTC | 50/122 | First | 27.3% | Response rate in control group: 15% | GEMOX + bevacizumab [156] | BTC | NA/35 | First & second | 40% | | Gem + triapine [157] | BTC | 18/33 | First | 9% | | 5FU/LV + imatinib [158] | BTC | 19/41 | First | 8% | | GEMOX + erlotinib [159] | BTC | 82/268 | First | 30% | 16% in chemotherapy arm alone. No difference in OS |
|
|
BTC, biliary tract cancer; GEMOX, gemcitabine and oxaliplatin; HCC, hepatocellular cancer; NA, not applicable; OS, overall survival. Modified from [143].
|